Objective: To compare the risk of adverse neonatal outcomes after frozen embryo transfer (FET) among women with polycystic ovary syndrome (PCOS) with those among women without PCOS.
Design: Retrospective cohort study.
Setting: Tertiary-care academic medical center.
Patient(s): In this study, we included 1,167 singletons born to mothers with PCOS and 9,995 singletons born to mothers without PCOS after FET during the period from January 1, 2007, to December 31, 2019.
Intervention(s): None.
Main Outcomes Measure(s): Adverse neonatal outcomes including preterm birth, low birth weight, high birth weight, small for gestational age (SGA), and large for gestational age.
Result(s): The odds of preterm birth were significantly higher among infants from mothers with PCOS compared with those from mothers without PCOS. The odds of low birth weight and SGA were lower in mothers with PCOS compared with mothers without PCOS in the overall analysis, but the differences in low birth weight and SGA between mothers with and without PCOS did not exist in the subgroup analysis with a normal BMI population.
Conclusion(s): The diagnosis of PCOS was independently associated with increased odds of preterm birth among women with singleton pregnancies by FET. In addition, decreased odds of low birth weight and SGA were observed among patients with PCOS, but the increased odds were not observed in the subset analysis of patients with PCOS with normal BMI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2020.08.1435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.
Reprod Biol Endocrinol
January 2025
Departments of Internal Medicine and Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 330 Cedar St, New Haven, CT, 06510, USA.
Background: Overweight and obesity-chronic illnesses in which an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass resulting in adverse metabolic, biomechanical, and psychosocial health consequences-negatively impact female fertility. Adverse conception outcomes are multifactorial, ranging from poor oocyte quality and implantation issues to miscarriages and fetal health issues. However, with the advent of novel pharmacologic agents, significant weight loss can be achieved, improving the chances of healthy pregnancies, and their use should be considered during periconceptual counseling.
View Article and Find Full Text PDFProspective associations of adolescent obesity phenotypes with self-reported polycystic ovary syndrome diagnosis in young adulthood.
Hum Reprod
January 2025
Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
Study Question: Are empirically derived adolescent overweight/obesity phenotypes differentially associated with polycystic ovary syndrome (PCOS) in young adulthood?
Summary Answer: Self-reported PCOS diagnosis risk in young adulthood varied by empirically derived adolescent overweight/obesity phenotypes, with the highest risk observed among those in the 'mothers with obesity' and 'early puberty' phenotypes.
What Is Known Already: Overweight and obesity during puberty are postulated to promote the development of PCOS. Much of the prior literature in this area is cross-sectional and defines weight status based solely on BMI, yet emerging research suggests that not all people with overweight/obesity have the same risk for chronic health conditions, including PCOS.
Unexpected delivery: cryptic pregnancy.
BMJ Case Rep
November 2024
Department of Obstetrics and Gynaecology, Leighton Hospital, Mid Cheshire Hospitals NHS Foundation Trust, Middlewich Road, Crewe, CW1 4QJ, UK.
Cryptic pregnancy was first described in the early 17th century and occurs when the pregnant person is unaware of their pregnant state and discovers this late in pregnancy or when labour starts. Historically, the term 'concealed pregnancy' has been used synonymously. In a concealed pregnancy, the patient is aware of their pregnancy but chooses to hide it.
View Article and Find Full Text PDFIs metformin safe in pregnancy: a focus on offspring outcomes.
Expert Opin Drug Saf
January 2025
Theodore E. Woodward Professor of Medicine, Chairman, Department of Medicine, University of Maryland School of Medicine, Physician-in-Chief, University of Maryland Medical Center, Baltimore, MD, USA.
Article Synopsis
- Metformin has been a staple in treating type 2 diabetes for years and is also used off-label for conditions like gestational diabetes and polycystic ovarian syndrome due to its insulin-sensitizing properties.
- In 2022, it became the only oral medication approved by the European Union for managing diabetes during pregnancy, showing safety and benefits for mothers while crossing the placenta to the baby.
- Benefits for mothers include reduced weight gain and lower risk of pre-eclampsia; however, long-term effects on their children are still uncertain, necessitating further research on potential concerns like small-for-gestational-age (SGA) outcomes.
The effects of fresh embryo transfer and frozen-thawed embryo transfer on the perinatal outcomes of single fetuses from mothers with PCOS.
PLoS One
October 2024
Reproductive Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Purpose: To investigate the effects of fresh embryo transfer and frozen-thawed embryo transfer on perinatal outcomes among patients with PCOS.
Method: Patients who underwent in vitro fertilization and embryo transfer at the reproductive medicine center of the Affiliated Hospital of Guangdong Medical University from February 2013 to March 2021 were retrospectively analyzed. Patients were divided into the fresh embryo transfer group and frozen-thawed embryo transfer group according to whether fresh embryo transfer was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!